文献速递肿瘤 PET/CT放射性药物与辐射防护

新诊断高危前列腺癌中FAPI、PSMA与FDG PET/CT的头对头比较

A Head-to-Head Comparison of Detection Rate and Tumor Uptake of FAPI, PSMA, and FDG PET/CT in Newly Diagnosed High-risk Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2026-10-20

该研究纳入48例活检确诊、未经治疗的高危前列腺癌患者,于2024年4月至12月间均行18F-AlF-NOTA-De-FAPI、68Ga-PSMA-11和18F-FDG PET/CT,头对头比较三种示踪剂的检出率和肿瘤摄取并分析双示踪表型。结果显示68Ga-PSMA-11总体检出率最高(96.4%),18F-AlF-NOTA-De-FAPI次之(81.1%),18F-FDG最低(66.0%),且FAPI可检出全部17个PSMA阴性病灶中的17个。

要点

  • 68Ga-PSMA-11总体检出率最高,为96.4%,FAPI为81.1%,FDG为66.0%。
  • 8例患者共17个PSMA阴性病灶均被FAPI检出,FDG仅检出其中12个。
  • PSMA与FAPI联合可检出三示踪剂PET检出的全部病灶。

核心结论

  • 18F-AlF-NOTA-De-FAPI是新诊断高危前列腺癌有前景的PET示踪剂,可提高68Ga-PSMA-11阴性病灶的检出率并提供反映病灶间异质性的互补信息。
  • 18F-AlF-NOTA-De-FAPI与68Ga-PSMA-11联合应用的临床价值尚需更大规模前瞻性队列进一步验证。

研究设计与样本

  • 研究纳入48例活检确诊、未经治疗的高危前列腺癌患者,于2024年4月至12月间均行18F-AlF-NOTA-De-FAPI、68Ga-PSMA-11和18F-FDG PET/CT。
  • 对三种示踪剂进行检出率和肿瘤摄取的头对头比较,并用18F-AlF-NOTA-De-FAPI与68Ga-PSMA-11双示踪PET刻画各病灶的影像表型及病灶间异质性。

主要发现

  • 三种PET示踪剂共检出477个病灶,68Ga-PSMA-11总体检出率最高(96.4%),18F-AlF-NOTA-De-FAPI为81.1%,18F-FDG为66.0%。
  • 8例患者中共发现17个68Ga-PSMA-11阴性病灶,均被18F-AlF-NOTA-De-FAPI检出,而18F-FDG仅检出其中12个。
  • 68Ga-PSMA-11联合18F-AlF-NOTA-De-FAPI PET可检出三示踪剂PET检出的全部病灶。
  • 基于双示踪PET的相对示踪剂优势,患者被分为PSMA优势型(n=23)、FAPI优势型(n=5)和混合表型(n=20)。
  • 混合表型伴显著病灶间异质性可能与更晚期临床特征相关,表现为转移性疾病比例更高和转移负荷更大。

关键数值与推荐

  • 68Ga-PSMA-11总体检出率为96.4%,18F-AlF-NOTA-De-FAPI为81.1%,18F-FDG为66.0%,共检出477个病灶。
  • 68Ga-PSMA-11阴性病灶共17个(见于8例患者),18F-AlF-NOTA-De-FAPI检出全部17个,18F-FDG检出12个。
  • 双示踪PET表型分类:PSMA优势型23例、FAPI优势型5例、混合表型20例。

临床怎么用

  • 对新诊断高危前列腺癌,68Ga-PSMA-11 PET总体检出率最高,可作为主导示踪剂。
  • 对68Ga-PSMA-11阴性或怀疑存在PSMA阴性病灶者,可补充18F-AlF-NOTA-De-FAPI PET以提高病灶检出。
  • 68Ga-PSMA-11与18F-AlF-NOTA-De-FAPI双示踪PET可刻画病灶间异质性并识别混合表型,后者可能与更晚期疾病相关。

局限性

  • 研究样本量为48例,双示踪表型与临床特征关联的结论需更大规模前瞻性队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study was designed to investigate the detection rate and tumor uptake of 18F-AlF-NOTA-De-FAPI PET/CT in newly diagnosed high-risk prostate cancer (PCa), compared with 68Ga-PSMA-11 and 18F-FDG PET/CT. PATIENTS AND METHODS: This study enrolled 48 patients with biopsy-diagnosed, treatment-naive high-risk PCa who underwent 18F-AlF-NOTA-De-FAPI, 68Ga-PSMA-11, and 18F-FDG PET/CT between April and December 2024. A head-to-head comparison of detection rate and tumor uptake was performed among the 3 tracers. In addition, 18F-AlF-NOTA-De-FAPI and 68Ga-PSMA-11 dual-tracer PET was used to characterize the imaging phenotypes of each lesion and interlesional heterogeneity. RESULTS: A total of 477 lesions were detected by the 3 PET tracers. 68Ga-PSMA-11 exhibited the highest overall detection rate (96.4%), followed by 18F-AlF-NOTA-De-FAPI (81.1%) and 18F-FDG (66.0%). A total of 17 68Ga-PSMA-11-negative lesions were identified in 8 patients, all of which were detected by 18F-AlF-NOTA-De-FAPI, whereas only 12 were detected by 18F-FDG. Combined 68Ga-PSMA-11 and 18F-AlF-NOTA-De-FAPI PET identified all lesions detected by triple-tracer PET. Based on relative tracer dominance of dual-tracer PET, patients were classified as PSMA-dominant (n=23), FAPI-dominant (n=5), or mixed phenotype (n=20). The mixed phenotype with marked interlesional heterogeneity might be associated with more advanced clinical characteristics, with a higher proportion of metastatic disease and a greater metastatic burden. CONCLUSIONS: 18F-AlF-NOTA-De-FAPI is a promising PET tracer for newly diagnosed high-risk PCa. It may improve the detection rate of 68Ga-PSMA-11-negative lesions and provide complementary information that could reflect interlesional heterogeneity. The clinical value of combining 18F-AlF-NOTA-De-FAPI and 68Ga-PSMA-11 PET requires further validation in larger prospective cohorts.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang W, Dong Y, Xu L, et al. A Head-to-Head Comparison of Detection Rate and Tumor Uptake of FAPI, PSMA, and FDG PET/CT in Newly Diagnosed High-risk Prostate Cancer. Clin Nucl Med. 2026. PMID: 42912579. doi:10.1097/RLU.0000000000006690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。